# US 2021/0174912 A1 · Data processing systems and methods for repurposing drugs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0174912 A1
- Document ID: US20210174912A1
- Status: Published application
- Kind: A1
- Application number: 17/116,995
- Filed: 2020-12-09
- Published: 2021-06-10
- Earliest claimed: 2019-12-09
- Assignees: Sanofi
- Applicants: Sanofi
- Inventors: Paul Bryce; Emanuele de Rinaldis; Ramon Antonio Hernandez Vecino; Francisco Javier Jimenez Jimenez; Cliona Marie Molony; Anne-Gaëlle Radenac
- Web page: https://patentgrep.com/patent/US20210174912A1

## CPC

- G16H 10/20: for electronic clinical trials or questionnaires
- G06N 20/00: Machine learning
- G16H 50/70: for mining of medical data, e.g. analysing previous cases of other patients
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G06N: COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS

## Abstract

Data processing systems for repurposing a drug can include a computer-readable memory including computer-executable instructions; and at least one processor configured to execute executable logic including the computer-executable instructions and at least one machine learning model to perform one or more operations. The one or more operations can include receiving data representing medical records of a plurality of patients; selecting a set of patients; determining a plurality of patient characteristics of the set of patients; grouping, in accordance with the plurality of patient characteristics, the set of patients to generate a plurality of distinct groups, each of the distinct groups including at least one patient of the set of patients; selecting, based on one or more group selection criteria, a set of distinct groups of the plurality of distinct groups; and identifying one or more relevant patient characteristics by analyzing each distinct group of the set of distinct groups.

## Claims

### Claim 1

A computer-implemented method for repurposing a drug, comprising:
receiving, by a computer system, data representing medical records of a plurality of patients;
selecting, based on the medical records, a set of patients by:
determining at least one target signaling pathway associated with the drug; and
determining one or more indicators based on one or more factors corresponding to a diagnosis linked to the target signaling pathway;
determining a plurality of patient characteristics of the set of patients, each patient of the set of patients exhibiting at least one of the plurality of patient characteristics;
grouping, by the computer system, in accordance with the plurality of patient characteristics, the set of patients to generate a plurality of distinct groups, each of the distinct groups including at least one patient of the set of patients;
selecting, based on one or more group selection criteria, a set of distinct groups of the plurality of distinct groups; and
identifying one or more relevant patient characteristics by analyzing each distinct group of the set of distinct groups.

### Claim 2 (depends on 1)

The method of claim 1, wherein grouping the set of patients comprises:
executing a machine learning system configured to perform one or more unsupervised clustering techniques.

### Claim 3 (depends on 2)

The method of claim 2, wherein the one or more unsupervised clustering techniques comprise a bisecting k-means clustering technique.

### Claim 4 (depends on 1)

The method of claim 1, wherein grouping the set of patients comprises performing multiple correspondence analysis to reduce dimensions of the plurality of patient characteristics.

### Claim 5 (depends on 1)

The method of claim 1, wherein selecting the set of distinct groups comprises:
determining, for each distinct group of the plurality of distinct groups, a feature score for each patient characteristic exhibited by that distinct group; and
comparing the feature score of each distinct group of the plurality of distinct groups to a feature score threshold.

### Claim 6 (depends on 1)

The method of claim 1, wherein selecting a set of distinct groups comprises at least one of: determining a stability measure for each distinct group of the plurality of distinct groups, determining a purity measure for each distinct group of the plurality of distinct groups, and determining a number of patients of the set of patients included in each distinct group of the plurality of distinct groups.

### Claim 7 (depends on 1)

The method of claim 1, wherein identifying the one or more relevant patient characteristics comprises:
generating a plurality of potentially relevant patient characteristics by, for each distinct group of the set of distinct groups, selecting the patient characteristics of the plurality of patient characteristics that are exhibited by that distinct group and correspond to a theme of that group; and
ranking each of the potentially relevant patient characteristics of the plurality of potentially relevant patient characteristics.

### Claim 8 (depends on 7)

The method of claim 7, wherein ranking each of the potentially relevant patient characteristics comprises, for each potentially relevant patient characteristic, assigning a rank value based on a frequency of co-occurrence of that potentially relevant patient characteristic and at least one referential indication associated with the drug.

### Claim 9 (depends on 8)

The method of claim 8, wherein the co-occurrence is measured by determining, for each of the potentially relevant patient characteristics, a proportion of the set of distinct groups that comprises both that potentially relevant patient characteristic and the at least one referential indication.

### Claim 10 (depends on 7)

The method of claim 7, wherein identifying the one or more relevant patient characteristics comprises determining, for each of the potentially relevant patient characteristics, at least one of: a clinical feasibility and a commercial feasibility.

### Claim 11

A data processing system for repurposing a drug, comprising:
a computer-readable memory comprising computer-executable instructions; and
at least one processor configured to execute executable logic including the computer-executable instructions and at least one machine learning model to perform one or more operations comprising:
receiving data representing medical records of a plurality of patients;
selecting, based on the medical records, a set of patients by:
determining at least one target signaling pathway associated with the drug; and
determining one or more indicators based on one or more factors corresponding to a diagnosis linked to the target signaling pathway;
determining a plurality of patient characteristics of the set of patients, each patient of the set of patients exhibiting at least one of the plurality of patient characteristics;
grouping, using the machine learning model and in accordance with the plurality of patient characteristics, the set of patients to generate a plurality of distinct groups, each of the distinct groups including at least one patient of the set of patients;
selecting, based on one or more group selection criteria, a set of distinct groups of the plurality of distinct groups; and
identifying one or more relevant patient characteristics by analyzing each distinct group of the set of distinct groups.

### Claim 12 (depends on 11)

The data processing system of claim 11, wherein the machine learning model is trained to group the set of patients using one or more unsupervised clustering techniques.

### Claim 13 (depends on 12)

The data processing system of claim 12, wherein the one or more unsupervised clustering techniques comprise a bisecting k-means clustering technique.

### Claim 14 (depends on 11)

The data processing system of claim 11, wherein grouping the set of patients comprises performing multiple correspondence analysis to reduce dimensions of the plurality of patient characteristics.

### Claim 15 (depends on 11)

The data processing system of claim 11, wherein selecting the set of distinct groups comprises:
determining, for each distinct group of the plurality of distinct groups, a feature score for each patient characteristic exhibited by that distinct group; and
comparing the feature score of each distinct group of the plurality of distinct groups to a feature score threshold.

### Claim 16 (depends on 11)

The data processing system of claim 11, wherein selecting a set of distinct groups comprises at least one of: determining a stability measure for each distinct group of the plurality of distinct groups, determining a purity measure for each distinct group of the plurality of distinct groups, and determining a number of patients of the set of patients included in each distinct group of the plurality of distinct groups.

### Claim 17 (depends on 11)

The data processing system of claim 11, wherein identifying the one or more relevant patient characteristics comprises:
generating a plurality of potentially relevant patient characteristics by, for each distinct group of the set of distinct groups, selecting the patient characteristics of the plurality of patient characteristics that are exhibited by that distinct group and correspond to a theme of that group; and
ranking each of the potentially relevant patient characteristics of the plurality of potentially relevant patient characteristics.

### Claim 18 (depends on 17)

The data processing system of claim 17, wherein ranking each of the potentially relevant patient characteristics comprises, for each potentially relevant patient characteristic, assigning a rank value based on a frequency of co-occurrence of that potentially relevant patient characteristic and at least one referential indication associated with the drug.

### Claim 19 (depends on 18)

The data processing system of claim 18, wherein the co-occurrence is measured by determining, for each of the potentially relevant patient characteristics, a proportion of the set of distinct groups that comprises both that potentially relevant patient characteristic and the at least one referential indication.

### Claim 20

A computer-implemented method for repurposing a drug, comprising:
receiving, by a computer system, data representing medical records of a plurality of patients;
selecting, based on the medical records, a set of patients by:
determining at least one target signaling pathway associated with the drug; and
determining one or more indicators based on one or more factors corresponding to a diagnosis linked to the target signaling pathway;
determining a plurality of patient characteristics of the set of patients, each patient of the set of patients exhibiting at least one of the plurality of patient characteristics;
grouping, by the computer system, in accordance with the plurality of patient characteristics, the set of patients to generate a plurality of distinct groups, each of the distinct groups including at least one patient of the set of patients;
selecting, based on one or more group selection criteria, a set of distinct groups of the plurality of distinct groups; and
identifying one or more relevant patient characteristics by analyzing each distinct group of the set of distinct groups;
identifying at least one of the one or more relevant patient characteristics as a target indication for repurposing the drug.
